Breast Cancer Clinical Trial

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Summary

The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in women with newly diagnosed breast cancer or DCIS who have had a lumpectomy procedure.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Female
Age >/= 45 years
Unicentric pathological stage I (pT1 or T2 pN0_M0) invasive ductal breast cancer or DCIS measuring <3 cm in longest diameter on pathology and or mammogram that is histologically confirmed. If T2, the tumor must be less than 3cm diameter. Note: Women ≥ 70 years older with T1 invasive ductal carcinoma who are estrogen- receptor positive (ER+) clinically negative axillary nodes, do not undergo surgical lymph node mapping dissection (i.e., if deposit 0.2 mm less, regardless of whether detected by immunohistochemistry hematoxylin eosin staining) will also eligible
Histologically negative tumor margin or no tumor in a re-excision specimen on final shaved specimen.
ECOG Performance Status of 0 or 1.
Clips must be placed in the lumpectomy cavity at the time of final excision in order to aid in the delineation of the tumor cavity at the time of simulation and radiation delivery.
Negative serum pregnancy test within 14 days prior to study treatment if a woman has child-bearing potential. Subjects of child bearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
Written informed consent obtained from subject and ability for subject or comply with the requirements of the study
Female subjects of childbearing potential should be willing to use 2 methods or birth control or be surgically sterile or abstain from heterosexual activity for the duration of study participation. Should a woman become pregnant while participating on study, she should inform the treating physician immediately.

Inclusion Criteria for intermediate risk substudy:

Post-NAC cohort patients: clinical T1 or T2 (less than or equal to 5cm in longest diameter on available imaging) and clinical N0 (on exam and imaging) with pathological pT0 or pTis and pN0 (any regimen of neoadjuvant chemotherapy agents is allowed)

OR

Oncotype RS score of 26 or higher

OR

PAM50 ROR scored as "HIGH"

OR

Presence or LVI (focal, limited or "not otherwise specified") in the lumpectomy specimen

OR

Age 40-49 years (ALL OF THE FOLLOWING MUST BE TRUE : 1) no history of prior benign breast biopsies, 2) no concomitant or prior atypia in either breast, 3) no concomitant or prior LCIS in either breast, 4) no family history of breast cancer in first degree relatives)

OR

Invasive lobular carcinoma

OR

Women 70 or older with tumors 2.0 cm or less in size and with clinically or pathologically negative nodes who decline or are ineligible for hormonal therapy OR discontinue hormonal therapy within 3 months of initiating treatment.

Exclusion Criteria:

Patients with distant metastasis
Patients who are pregnant or breastfeeding
Patients with diffuse (>1 quadrant or >5cm) suspicious microcalcifications or patients with known multicentric OR multifocal disease. (microscopic multifocal disease that may be unifocal and/or appear multifocal due to sectioning is allowed after review with PI).
Prior radiation therapy to the ipsilateral or contralateral breast or thorax.
Histological evidence of extensive lymphovascular invasion (LVI)
Histological evidence of extensive intraductal component (EIC), defined as the presence of intraductal carcinoma both within the primary infiltrating ductal tumor (comprising at least 25% of the tumo area) and intraductal carcinoma present clearly beyond the edges of the invasive tumor.
Patients are not required to undergo BRCA1 and BRCA2 or other genetic mutation tests in order to enroll on the study. Note: in the event a patient is tested and is found to be a mutation carrier, she would be excluded from the study. It would be an extremely rare/unlikely scenario for patients to be discovered BRCA positive after the completion of PBI, as all patients with risk factors for BRCA mutations (positive family history, Ashkenazi Jewish descent, ER-/PR-/her2-neu-negative receptor status) are usually tested prior to radiation. Should such a situation exist, these patients will be given the option of remaining on the breast conservation paradigm or opting for mastectomy (as is done in this rare scenario is standard of care practice). The patient will be replaced on the trial.
History of cosmetic or reconstructive breast surgery.
Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have "currently active" malignancies if they have completed therapy and are considered by their physicians to be at <5% risk of relapse within 3 years.
Patients who are already enrolled in or planning to enroll in other adjuvant systemic therapy protocols for both non-invasive or invasive breast cancer
Expecting to conceive within the projected duration of the trials, starting with screening visit through 180 days after the last dose of trial treatment
Concomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least 2 weeks prior to commencement of protocol treatment, with resolution of associated acute toxicities. Bisphosponates are permitted without restriction even during protocol treatment. Note: This does not apply to hormonal therapies such as tamoxifen or AIs, which are permitted. This does not apply to anti-Her2 therapies such as trastuzumab or TDM-1, which are also permitted.
Ongoing therapy with other investigational agents. Patients may not be receiving any other investigational agents.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

140

Study ID:

NCT04084730

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

Norwalk Hospital
Norwalk Connecticut, 06850, United States More Info
Philip Gilbo, MD
Contact
203-845-4811
Baptist Alliance Miami Cancer Institute
Miami Florida, 33143, United States More Info
Joseph Panoff, MD
Contact
786-596-2000
Memorial Sloan Kettering Basking Ridge
Basking Ridge New Jersey, 07920, United States More Info
Atif J Khan, MD
Contact
848-225-6334
Memorial Sloan Kettering Monmouth
Middletown New Jersey, 07748, United States More Info
Atif J Khan, MD
Contact
848-225-6334
Memorial Sloan Kettering Bergen
Montvale New Jersey, 07645, United States More Info
Atif J Khan, MD
Contact
848-225-6334
Memorial Sloan Kettering Commack
Commack New York, 11725, United States More Info
Atif J Khan, MD
Contact
848-225-6334
Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States More Info
Atif J Khan, MD
Contact
848-225-6334
Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States More Info
Atif J Khan, MD
Contact
848-225-6334
Memorial Sloan Kettering Nassau
Uniondale New York, 11553, United States More Info
Atif J Khan, MD
Contact
848-225-6334

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

140

Study ID:

NCT04084730

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.